TESTING OF NEUROPROTECTIVE COMPOUNDS IN A TRANSGENIC MOUSE MODEL OF HUNTINGTON’S DISEASE PhD Thesis

Klivényi P (2011) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. survival and the motor performance in a transgenic mouse model of Huntington's disease. Total impact factor of original papers directly related to the thesis: 5.226 Publications not directly related to the thesis I. in chronic neurodegenerative disorders: with particular regard to the kynurenines. chronic neurodegenerative disorders: future therapeutic strategies. probenecid in a transgenic animal model of Huntington's disease. ZL (2008) Differences between normal and alpha-synuclein overexpressing SH-SY5Y 2 neuroblastoma cells after Abeta(1-42) and NAC treatment. The role of chronic brain hypoperfusion in the pathogenesis of Alzheimer's disease – facts and hypothesis. Ideggyogy Sz 60: 428-37 (2004) In vitro model of neurotoxicity of Abeta 1-42 and neuroprotection by a pentapeptide: irreversible events during the first hour. (2003) Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells.